Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

Recent health headlines spotlight Surgery Partners rejecting Bain Capital's offer, the U.S. betting on China's drug potential ...

Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new ...

Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

Trading platform Uphold, which holds 1.8 billion XRP, is looking to integrate FXRP. Separately, NASDAQ-listed VivoPower has ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. UBS upgraded ...

For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

Solar stocks slid in off-hours trading after Senate Republicans kept in a full phase-out of solar and wind energy tax credits in [President Trump's budget bill]( ...

After reaching a high of $19.99, Avalanche’s token AVAX was sharply rejected at the $20 psychological barrier, triggering accelerated selling that drove prices down to $18.61, according to CoinDesk ...